profile patients

LONDON, UK: Oncimmune Holdings has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases. The initial phase of this project, including the reporting of profiled data, is scheduled to complete by the end of calendar year 2021. Under this agreement, Oncimmune…